Preventing infections with GLP-1 receptor agonists

Glucagon-like peptide-1 receptor agonists could be associated with a reduced risk of infection across multiple organ systems.

In a systematic review and meta-analysis published in the Journal of Infection, investigators used the PubMed, EMBASE, Cochrane Library and Web of Science databases to identify 136 randomized controlled trials reporting on infections among patients receiving GLP-1 receptor agonists or placebo.

Compared with those who received placebo, the patients who received GLP-1 receptor agonists were less likely to experience serious and nonserious respiratory, skin and subcutaneous, musculoskeletal, vascular and COVID-19 infections. The investigators noted that higher doses of GLP-1 receptor agonists as well as greater weight and glycemic control partially explained the lower observed infection risk among the GLP-1 receptor agonist group.

Further studies are needed to better understand how GLP-1 receptor agonists can curb infections.

Read more: Journal of Infection

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.